health NICE Approves Sparsentan for Kidney Disease Treatment [ad_1] The National Institute for Health and Care Excellence (NICE) has recommended sparsentan (Filspari, Vifor Pharma) for treating… bynewsdeskMay 28, 2025
health GLP-1 Benefits, Risks Detailed in ‘Atlas’ Mapping Outcomes [ad_1] A study of more than two million people with diabetes builds on evidence of broad-ranging benefits and… bynewsdeskJanuary 24, 2025
